Epac contributes to cardiac hypertrophy and amyloidosis induced by radiotherapy but not fibrosis
Virginie Monceau(CEA Paris-Saclay - Etablissement de Fontenay-aux-roses), Marie‐Catherine Vozenin(University of Geneva), D. Azria(Inserm), Benoît Petit(Université Paris-Sud), Sophie Gourgou(Université de Montpellier), Julia Haagen(University Hospital Carl Gustav Carus), Ana M. Gómez(Nationwide Children's Hospital), Anna Llach(Hospital de Sant Pau), T. To(Université Paris-Sud), P. Fenoglietto(CEA Valduc), L. Calmels(Institut Gustave Roussy), Carine Strup-Perrot(Institut de Radioprotection et de Sûreté Nucléaire), Éric Morel(Inserm), C. Bourgier(Inserm), A. Bridier(Institut Gustave Roussy), Brigitte Escoubet, Marie-Michèle Germaini(Inserm), Marianne Mazevet(Inserm), Wolfgang Dörr(Goethe University Frankfurt), Éric Deutsch(Inserm)
Cited by 28
Related Papers
Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors
|Science|2017|5.4k
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer
|New England Journal of Medicine|2018|2.9k
Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial
|The Lancet Oncology|2021|1.3k
High-Throughput Genomics and Clinical Outcome in Hard-to-Treat Advanced Cancers: Results of the MOSCATO 01 Trial
|Cancer Discovery|2017|781
Zircon M257 ‐ a Homogeneous Natural Reference Material for the Ion Microprobe U‐Pb Analysis of Zircon
|Geostandards and Geoanalytical Research|2008|669